Biome Australia (ASX:BIO): What's Pushing This Microbiome Health Stock Higher This Week?

Sonal Goyal

17 September 2026 03:33 AM AEST

Biome Australia (ASX:BIO): What's Pushing This Microbiome Health Stock Higher This Week?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Biome Australia will launch two new products in H1 FY27: Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60, two-month formats of its two highest-volume products.
Biome Daily and Biome Daily Kids are ranked as the number one probiotic products in Australian pharmacy by both units and value, based on IQVIA pharmacy scan data.
The new products will be Biome's first Australian-made items, manufactured under its onshore agreement with Specialty Probiotics Australia.
The launches are designed to spread Demand across more SKUs, de-risking Supply of the company's two largest product lines.

Biome Australia Limited (ASX:BIO) shares closed at $0.43 on 17 September 2026, up 10.26% or 4 cents on the day, among the stronger performers on the market. The move might follows the company's announcement on 9 September 2026 detailing plans to launch two new products in the first half of FY27, expanding its Activated Probiotics range into larger pack formats.

The microbiome health company, which develops and markets evidence-based probiotics and complementary medicines, said the launches target a segment of the Australian pharmacy market currently dominated by competitors' larger pack sizes.

New Product Launches

Biome confirmed it will launch Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60 in the first half of FY27, representing two-month supply formats of the company's two highest-volume products, which are currently sold in 30-capsule and 30-sachet packs respectively.

Both products are described as clinically supported daily probiotics addressing gastrointestinal symptoms, the side effects of antibiotics, and winter immune support, using microencapsulation technology that the company says allows five times more live bacteria to reach the gut compared with uncoated probiotics.

Biome Daily Probiotic is a six-strain, 9 billion live bacteria capsule for adults, combining the HEAL9 and 8700:2 strains studied in placebo-controlled trials involving more than 1,400 adults. Biome Daily Kids Probiotic is a five-strain, 10 billion live bacteria vanilla-flavoured sachet for children from age two, formulated to support immune function and includes Lactobacillus rhamnosus GG.

Market Position and Category Data

According to independent IQVIA pharmacy scan data cited by the company, Biome Daily is ranked the number one probiotic product in Australian pharmacy by both units and value, while Biome Daily Kids is ranked the number one immune health and kids probiotic. Both products reached these rankings in 30-pack formats, against competing brands whose core lines are sold in 60 and 90-pack formats.

The same data indicates that 14 of the top 20 probiotic products in Australian pharmacy by value are sold in 60 or 90-pack formats, and that three of the six 30-pack products in the top 20 are Biome's own. The company said the new 60-pack products bring its two category-leading lines into the pack format that leads the broader category.

Commercial Rationale

Biome said the rationale for the two-month format is rooted in supporting patient adherence, noting that probiotics work through consistent daily use and that the most common reason patients discontinue use is running out of product. The company said pricing has been set to retain existing customers as they transition to the larger format.

Both new products will be supplied through Biome's existing community pharmacy wholesalers and practitioner channel from the first half of FY27, spreading demand that currently sits on a single SKU across two SKUs and reducing the impact of any stock-out at wholesaler or retailer level. Biome's modelling indicates growth in new sales is expected to run well ahead of any substitution from existing 30-pack sales, though the company did not provide Revenue guidance for the new products.

Manufacturing Shift

The two new products will be Biome's first Australian-made items, manufactured under its onshore Manufacturing agreement with Specialty Probiotics Australia, first announced on 3 June 2026. The company said the format is structurally more efficient, requiring one carton, one label and one freight movement to cover two months of supply, supporting its stated objective of lifting gross Margin as manufacturing moves onshore.

What to Watch Next

Investors will likely watch for confirmation of the specific launch timing within H1 FY27, as well as early sales data once the new 60-pack products reach pharmacy shelves through Biome's wholesaler and practitioner channels. Given the company provided no formal revenue guidance, subsequent trading updates or quarterly reports may be the first indication of how the new formats are performing relative to the 30-pack base.

Risks

The company's own modelling assumptions around limited substitution from existing 30-pack sales represent a key variable; if new format sales cannibalise existing SKUs more than expected, the net revenue benefit could be smaller than anticipated. As with any manufacturing transition, the shift to onshore production under the Specialty Probiotics Australia agreement carries execution risk around supply continuity during the changeover.

Biome's forward-looking statements caution that no representation or warranty is made as to the accuracy or achievement of any guidance regarding future revenues, and that actual performance may differ from current expectations.

Key Takeaways

Biome Australia's move into larger pack formats represents an attempt to capture share within a segment of the Australian pharmacy probiotic category that its own market-leading 30-pack products have not yet addressed. With IQVIA data showing that the majority of top-selling probiotics in the category come in 60 or 90-pack formats, the launch of Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60 targets a demonstrated gap in the company's own product range. The shift to Australian-made manufacturing adds a further operational dimension to the announcement, though the ultimate commercial outcome will depend on how much of the new format's sales represent genuine incremental Volume versus a shift from the company's existing 30-pack lines.

FAQs

Q: What new products is Biome Australia launching?

A: Biome will launch Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60, two-month supply formats of its two highest-volume probiotic products, in the first half of FY27.

Q: Are Biome Daily and Biome Daily Kids market leaders?

A: According to IQVIA pharmacy scan data cited by the company, Biome Daily is the number one probiotic product in Australian pharmacy by units and value, and Biome Daily Kids is the number one immune health and kids probiotic.

Q: Where will the new products be manufactured?

A: The new products will be Biome's first Australian-made items, manufactured under its onshore agreement with Specialty Probiotics Australia, announced on 3 June 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.